Know Cancer

forgot password

A Phase III Randomized, Double-Blind Study of Maintenance Therapy With CC-5013 [NSC # 703813, IND #70116] or Placebo Following Autologous Stem Cell Transplantation for Multiple Myeloma

Phase 3
18 Years
70 Years
Open (Enrolling)
Multiple Myeloma and Plasma Cell Neoplasm

Thank you

Trial Information

A Phase III Randomized, Double-Blind Study of Maintenance Therapy With CC-5013 [NSC # 703813, IND #70116] or Placebo Following Autologous Stem Cell Transplantation for Multiple Myeloma



- Compare the efficacy of lenalidomide vs placebo as maintenance therapy after autologous
stem cell transplantation, in terms of prolonging time to disease progression, in
patients with multiple myeloma (arm II closed as of 12/17/09).


- Compare the rate of complete response in patients treated with these regimens (arm II
closed as of 12/17/09).

- Compare the progression-free and overall survival of patients treated with these
regimens (arm II closed as of 12/17/09).

- Determine the feasibility of long-term treatment with lenalidomide in these patients.

OUTLINE: This is a randomized, double-blind, placebo-controlled, multicenter study.

- Peripheral blood stem cell (PBSC) mobilization: Mobilization of autologous peripheral
blood stem cells will be performed according to institutional guidelines. Stem cells
may be collected at any time prior to transplant.

- Autologous PBSC transplantation (PBSCT): Approximately 2-4 weeks after PBSC collection,
patients receive melphalan IV either over 30-60 minutes on day -2 or as a divided dose
over two days on days -3 and -2 or days -2 and -1. Patients undergo autologous PBSCT on
day 0. Patients receive G-CSF SC once daily after day 0 but before day 5 and continuing
until blood counts recover.

- Maintenance therapy*: Approximately 90-100 days after completion of autologous PBSCT,
patients undergo restaging. Patients with disease progression are removed from the
study. Patients with responding or stable disease are stratified according to levels of
β2 microglobulin at baseline (≥ 2.5 mg/dL vs normal), prior thalidomide (yes vs no),
and prior lenalidomide (yes vs no). Patients are randomized to 1 of 2 maintenance
treatment arms (arm II closed as of 12/17/09).

- Arm I: Beginning between day 100-110, patients receive oral lenalidomide once

- Arm II (closed as of 12/17/09): Beginning between day 100-110, patients receive
oral placebo once daily. Patients who have not yet met the study endpoint receive
oral lenalidomide as in arm I at the discretion of treating physician.

In both arms, treatment continues in the absence of disease progression or unacceptable
toxicity (arm II closed as of 12/17/09) .

NOTE: *The maintenance dose is increased to a maximum dose of 3 pills over 3-6 months.

Treatment assignments were unblinded on 12/17/2009. As of 12/17/2009, no more patients will
be randomized between lenalidomide and placebo.

After completion of study treatment, patients are followed every 3 months for 4 years, every
6 months for 5 years, and then annually for 6 years.

PROJECTED ACCRUAL: A total of 538 will be accrued for this study.

Inclusion Criteria


- Diagnosis of multiple myeloma

- Active disease requiring treatment

- Durie-Salmon Stage I, II, or III

- Stable disease or responsive after ≥ 2 months of any induction therapy initiated
within the past year

- No prior disease progression after initial therapy

- Patients with smoldering myeloma are eligible provided disease has progressed to ≥
stage I



- 18 to 70

Performance status

- ECOG 0-1

Life expectancy

- Not specified


- Absolute neutrophil count ≥ 1,000/mm^3

- Platelet count ≥100,000/mm^3


- Hepatitis B surface antigen negative

- Hepatitis C negative

- Bilirubin ≤ 2 mg/dL

- AST ≤ 3 times upper limit of normal (ULN)

- Alkaline phosphatase ≤ 3 times ULN


- Creatinine clearance ≥ 40 mL/min

- Creatinine ≤ 2 mg/dL


- LVEF ≥ 40% by MUGA or echocardiogram


- DLCO > 50% of predicted

- No symptomatic pulmonary disease


- Not pregnant or nursing

- Negative pregnancy test

- Fertile patients must use effective double-method contraception

- HIV negative

- No uncontrolled diabetes mellitus

- No serious active infection


- Prior thalidomide or lenalidomide allowed provided treatment duration was ≤ 12 months

- No prior bone marrow or peripheral blood stem cell transplantation

- No prior solid organ transplantation

- Prior therapy allowed provided treatment duration was ≤ 12 months

- No more than two prior regimens (not including dexamethasone alone)

- No concurrent pegfilgrastim

- Peripheral blood stem cell (PBSC) collection of ≥ 2 x 10^6 CD34+ cells/kg (patient
body weight) and preferably 5 x 10^6 cells/kg (patient body weight)

- Stem cells may be collected at any time prior to transplant

- PBSC collection may occur before or after registration

Type of Study:


Study Design:

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment

Outcome Measure:

Time to progression

Outcome Time Frame:

30 months

Safety Issue:


Principal Investigator

Philip L. McCarthy, MD

Investigator Role:

Study Chair

Investigator Affiliation:

Roswell Park Cancer Institute


United States: Food and Drug Administration

Study ID:




Start Date:

December 2004

Completion Date:

July 2019

Related Keywords:

  • Multiple Myeloma and Plasma Cell Neoplasm
  • stage I multiple myeloma
  • stage II multiple myeloma
  • stage III multiple myeloma
  • Neoplasms
  • Multiple Myeloma
  • Neoplasms, Plasma Cell
  • Plasmacytoma



Roswell Park Cancer Institute Buffalo, New York  14263
Memorial Sloan-Kettering Cancer Center New York, New York  10021
Mayo Clinic Scottsdale Scottsdale, Arizona  85259
Mayo Clinic - Jacksonville Jacksonville, Florida  32224
Mayo Clinic Cancer Center Rochester, Minnesota  55905
Walter Reed Army Medical Center Washington, District of Columbia  20307-5000
University of Chicago Cancer Research Center Chicago, Illinois  60637
CCOP - Kansas City Kansas City, Missouri  64131
CCOP - Illinois Oncology Research Association Peoria, Illinois  61602
Aurora Presbyterian Hospital Aurora, Colorado  80012
Boulder Community Hospital Boulder, Colorado  80301-9019
Penrose Cancer Center at Penrose Hospital Colorado Springs, Colorado  80933
CCOP - Colorado Cancer Research Program Denver, Colorado  80224-2522
Porter Adventist Hospital Denver, Colorado  80210
Presbyterian - St. Luke's Medical Center Denver, Colorado  80218
St. Joseph Hospital Denver, Colorado  80218
Rose Medical Center Denver, Colorado  80220
Swedish Medical Center Englewood, Colorado  80110
St. Mary's Regional Cancer Center at St. Mary's Hospital and Medical Center Grand Junction, Colorado  81502
Sky Ridge Medical Center Lone Tree, Colorado  80124
Hope Cancer Care Center at Longmont United Hospital Longmont, Colorado  80502
St. Mary - Corwin Regional Medical Center Pueblo, Colorado  81004
North Suburban Medical Center Thornton, Colorado  80229
Jewish Hospital Cancer Center Cincinnati, Ohio  45236
Abramson Cancer Center of the University of Pennsylvania Philadelphia, Pennsylvania  19104-4283
Geisinger Medical Group - Scenery Park State College, Pennsylvania  16801
Frank M. and Dorothea Henry Cancer Center at Geisinger Wyoming Valley Medical Center Wilkes-Barre, Pennsylvania  18711
Vanderbilt-Ingram Cancer Center Nashville, Tennessee  37232-6838
University of Wisconsin Paul P. Carbone Comprehensive Cancer Center Madison, Wisconsin  53792-6164
Marshfield Clinic - Marshfield Center Marshfield, Wisconsin  54449
Medical College of Wisconsin Cancer Center Milwaukee, Wisconsin  53226
Froedtert Hospital and Medical College of Wisconsin Milwaukee, Wisconsin  53226-3596
Methodist Medical Center of Illinois Peoria, Illinois  61636
LDS Hospital Salt Lake City, Utah  84143
Lineberger Comprehensive Cancer Center at University of North Carolina - Chapel Hill Chapel Hill, North Carolina  27599-7570
Rebecca and John Moores UCSD Cancer Center La Jolla, California  92093-0658
University of California Davis Cancer Center Sacramento, California  95817
Dana-Farber/Harvard Cancer Center at Dana Farber Cancer Institute Boston, Massachusetts  02115
City of Hope Comprehensive Cancer Center Duarte, California  91010
Fletcher Allen Health Care - University Health Center Campus Burlington, Vermont  05401
Long Island Jewish Medical Center New Hyde Park, New York  11040
University of Florida Shands Cancer Center Gainesville, Florida  32610-0232
Mount Sinai Medical Center New York, New York  10029
SUNY Upstate Medical University Hospital Syracuse, New York  13210
Wake Forest University Comprehensive Cancer Center Winston-Salem, North Carolina  27157-1096
Baylor University Medical Center - Houston Houston, Texas  77030-2399
Lahey Clinic Medical Center - Burlington Burlington, Massachusetts  01805
James P. Wilmot Cancer Center at University of Rochester Medical Center Rochester, New York  14642
North Colorado Medical Center Greeley, Colorado  80631
McKee Medical Center Loveland, Colorado  80539
UNMC Eppley Cancer Center at the University of Nebraska Medical Center Omaha, Nebraska  68198-7680
New York Weill Cornell Cancer Center at Cornell University New York, New York  10021
UCSF Helen Diller Family Comprehensive Cancer Center San Francisco, California  94115
MBCCOP - Medical College of Georgia Cancer Center Augusta, Georgia  30912-3730
Mountain States Tumor Institute at St. Luke's Regional Medical Center Boise, Idaho  83712-6297
University of Illinois Cancer Center Chicago, Illinois  60612-7243
Indiana University Melvin and Bren Simon Cancer Center Indianapolis, Indiana  46202-5289
Masonic Cancer Center at University of Minnesota Minneapolis, Minnesota  55455
University of Mississippi Cancer Clinic Jackson, Mississippi  39216-4505
Siteman Cancer Center at Barnes-Jewish Hospital - Saint Louis St. Louis, Missouri  63110
Cancer Institute of New Jersey at UMDNJ - Robert Wood Johnson Medical School New Brunswick, New Jersey  08903
Don Monti Comprehensive Cancer Center at North Shore University Hospital Manhasset, New York  11030
Knight Cancer Institute at Oregon Health and Science University Portland, Oregon  97239-3098
Geisinger Cancer Institute at Geisinger Health Danville, Pennsylvania  17822-0001
M. D. Anderson Cancer Center at University of Texas Houston, Texas  77030-4009
Arthur G. James Cancer Hospital and Solove Research Institute at Ohio State University Medical Center Columbus, Ohio  43210-1240
Fox Chase Cancer Center - Philadelphia Philadelphia, Pennsylvania  19111-2497
UPMC Cancer Centers Pittsburgh, Pennsylvania  15232
Graham Hospital Canton, Illinois  61520
Memorial Hospital Carthage, Illinois  62321
Eureka Community Hospital Eureka, Illinois  61530
Galesburg Cottage Hospital Galesburg, Illinois  61401
Mason District Hospital Havana, Illinois  62644
Hopedale Medical Complex Hopedale, Illinois  61747
McDonough District Hospital Macomb, Illinois  61455
BroMenn Regional Medical Center Normal, Illinois  61761
Community Cancer Center Normal, Illinois  61761
Community Hospital of Ottawa Ottawa, Illinois  61350
Cancer Treatment Center at Pekin Hospital Pekin, Illinois  61554
Oncology Hematology Associates of Central Illinois, PC - Peoria Peoria, Illinois  61615
Proctor Hospital Peoria, Illinois  61614
Illinois Valley Community Hospital Peru, Illinois  61354
Perry Memorial Hospital Princeton, Illinois  61356
St. Margaret's Hospital Spring Valley, Illinois  61362
Providence Cancer Center at Providence Portland Medical Center Portland, Oregon  97213-2967
Mountainview Medical Berlin, Vermont  05602
St. Anthony Central Hospital Denver, Colorado  80204-1335
Exempla Lutheran Medical Center Wheat Ridge, Colorado  80033
North Kansas City Hospital Kansas City, Missouri  64116
Saint Luke's Cancer Institute at Saint Luke's Hospital Kansas City, Missouri  64111
Legacy Good Samaritan Hospital & Comprehensive Cancer Center Portland, Oregon  97210
Geisinger Hazleton Cancer Center Hazleton, Pennsylvania  18201
Methodist Hospital Houston, Texas  77030
Dana-Farber/Brigham and Women's Cancer Center Boston, Massachusetts  02115
Galesburg Clinic, PC Galesburg, Illinois  61401
St. Mary's Regional Cancer Center at St. Mary's Medical Center Huntington, West Virginia  25702
Ralph Lauren Center for Cancer Care and Prevention New York, New York  10035